<DOC>
	<DOCNO>NCT00106613</DOCNO>
	<brief_summary>The purpose study evaluate activity FK228 metastatic renal cell carcinoma ( RCC ) patient develop progressive disease ( PD ) follow treatment immunotherapy .</brief_summary>
	<brief_title>A Research Study Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patients must fulfill follow criterion eligible study participation : Age ≥ 18 year ; Histologically confirm Renal Cell Carcinoma ( RCC ) ; Metastatic disease , measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) ; Failure prior cytokine therapy ; Documented progressive disease ; Patients ineligible entry follow criterion meet : Significant cardiac disease include congestive heart failure , history myocardial infarction within one year , uncontrolled dysrhythmias , poorly control angina History serious ventricular arrhythmia Corrected QT interval ( QTc ) ≥ 500 msec Known infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C ; Previous extensive radiotherapy involve ≥ 30 % bone marrow Coexistent second malignancy history prior malignancy within previous 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
</DOC>